Evercore ISI Forecasts Strong Price Appreciation for Envista (NYSE:NVST) Stock

Envista (NYSE:NVST) had its price target lifted by stock analysts at Evercore ISI from $19.00 to $23.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Evercore ISI’s price target indicates a potential upside of 13.52% from the stock’s current price.

Several other brokerages also recently commented on NVST. Bank of America reduced their price objective on shares of Envista from $26.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, April 29th. Piper Sandler cut their target price on Envista from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. UBS Group cut their target price on Envista from $21.00 to $18.00 and set a “neutral” rating on the stock in a report on Monday, May 5th. Baird R W upgraded Envista from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 27th. Finally, Morgan Stanley set a $16.00 target price on Envista in a report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Envista presently has an average rating of “Hold” and an average price target of $20.23.

Envista Stock Performance

Shares of NVST stock opened at $20.26 on Wednesday. The company has a market cap of $3.43 billion, a price-to-earnings ratio of -3.10, a price-to-earnings-growth ratio of 1.25 and a beta of 1.00. Envista has a 52 week low of $14.22 and a 52 week high of $23.00. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.43. The firm has a 50 day moving average of $18.41 and a 200-day moving average of $18.48.

Envista (NYSE:NVST) last announced its quarterly earnings data on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. The company had revenue of $616.90 million during the quarter, compared to the consensus estimate of $608.17 million. Envista had a negative net margin of 44.90% and a positive return on equity of 4.07%. The company’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.26 EPS. On average, equities analysts forecast that Envista will post 1 earnings per share for the current year.

Institutional Investors Weigh In On Envista

A number of hedge funds have recently made changes to their positions in the business. Treasurer of the State of North Carolina raised its stake in shares of Envista by 0.6% during the 4th quarter. Treasurer of the State of North Carolina now owns 75,560 shares of the company’s stock worth $1,458,000 after purchasing an additional 480 shares during the period. M&T Bank Corp raised its stake in shares of Envista by 4.2% during the 4th quarter. M&T Bank Corp now owns 16,621 shares of the company’s stock worth $320,000 after purchasing an additional 676 shares during the period. Assetmark Inc. increased its holdings in Envista by 2.5% in the 4th quarter. Assetmark Inc. now owns 39,624 shares of the company’s stock worth $764,000 after acquiring an additional 983 shares during the last quarter. Xponance Inc. increased its holdings in Envista by 5.8% in the 4th quarter. Xponance Inc. now owns 19,726 shares of the company’s stock worth $381,000 after acquiring an additional 1,077 shares during the last quarter. Finally, Palouse Capital Management Inc. increased its holdings in Envista by 14.4% in the 1st quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company’s stock worth $163,000 after acquiring an additional 1,186 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.